Daily Stock List
Medbox, Inc. (MDBX)
SmallCapVoice, The Street, and StreetInsider reported on Medbox, Inc. (MDBX), and we choose to highlight the Company as well, here at the QualityStocks Daily Newsletter.
Medbox, Inc. provides specialized consulting services to the legal marijuana industry. In addition, it sells associated patented products, including its Medbox medical dispensing system and medical vaporization devices. The Company is a leading dispensary infrastructure/licensing specialist, patented technology provider, and partner to the cannabis industry. It provides its patented systems, software and consulting services to pharmacies, alternative medicine dispensaries, and local governments in the U.S. Medbox is based in Los Angeles, California.
The Company uses its expertise to work with investors and entrepreneurs who look to enter the cannabis sector. Medbox provides them with a high quality, turn-key solution, consisting of licensing, site selection, permitting, design, and full build-out. Medbox has become a leader in providing compliance, safety, security, oversight and operational expertise to the medical and recreational cannabis industry nationwide. Additionally, it has its wholly-owned subsidiary, Vaporfection International, Inc. Through this subsidiary, it provides an industry award-winning medical line of vaporizer products.
Medbox is also developing supplementary services customized to the alternative medicine industry. This includes real estate acquisitions and subsequent lease programs to alternative medicine dispensaries and cultivation centers, and alternative medicine dispensary and cultivation management services. The Company also engages in merchant services and armored transport for cash deposits - ancillary services catered to the alternative medicine industry.
Medbox features patented systems that dispense medication based on biometric identification (fingerprint sample). Its systems enable pharmacies, assisted living facilities, prisons, hospitals, doctors’ offices, and alternative medicine clinics to help manage employee possession of sensitive drugs. In a retail environment characteristic in most alternative medicine clinics, the system lets the clinics document that the user is a registered patient and that the patient has a valid and unexpired authorization from a physician to possess and use the medicine dispensed.
Medbox has its patented “Medbox”. The biometrically sealed inventory control, storage and dispensing technology ensures safe and secure access to marijuana in medical and recreational dispensaries.
Recently, Medbox announced that its wholly-owned subsidiary, Vaporfection, signed an exclusive North American distribution agreement for its "miVape" vaporizer with VaporNation. The miVape vaporizer is a self-contained, USB-rechargeable unit, which uses medical grade, food-safe and heat resistant materials to deliver the healthiest experience possible. VaporNation is the largest wholesaler and online retailer of vaporizers.
Medbox, Inc. (MDBX), closed Wednesday's trading session at $0.115, down 10.16%, on 1,762,482 volume with 221 trades. The average volume for the last 60 days is 565,869 and the stock's 52-week low/high is $0.1125/$18.54.
Baristas Coffee Company, Inc. (BCCI)
PennyStockRumors.net, PricelessPennyStocks, and SmallCapVoice reported earlier on Baristas Coffee Company, Inc. (BCCI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Baristas Coffee Company, Inc. established to create a national brand of drive-thru espresso stands. The Company is accomplishing this through acquiring established businesses that fit its model, opening new locations, and by franchising. Baristas Coffee Company is the largest and fastest growing costume-themed drive through Espresso Company in the nation. The Company lists on the OTC Markets’ OTCQB. Baristas Coffee Company has its corporate head office in Kent, Washington.
Baristas Coffee Company can be found in seven greater Seattle area locations, and also in Florida, and Montana. It has company owned locations and has begun franchising. In addition, Baristas has also commenced opening locations in shopping malls.
The Company has its theme of joining attractive female baristas in entertaining costumes preparing premium beverages (Seattle's World Famous Costume Coffee). Baristas provides its customers hot and cold beverages, specializing in specialty coffees, blended teas, and other custom drinks.
In addition, the Company offers smoothies, fresh-baked pastries, and other confections. In season, it adds beverages including hot apple cider, hot chocolate, frozen coffees, and more. Another revenue stream for Baristas is in promoting and selling Baristas™ merchandise; alluring calendars, mugs, t-shirts, and hats.
Baristas Coffee Company’s third shopping mall location recently started its remodel in Johnstown, Pennsylvania, with eight state master franchise partner BMOC Partners. The location is a 1,000-square-foot inline space at the Johnstown Mall, Johnstown, Pennsylvania. BMOC is a regional hospitality and Franchise operations enterprise. BMOC’s founders have extensive experience in creating, marketing, and also running multiple franchise systems.
In May, Baristas Coffee Company announced that it entered into a joint venture (JV) agreement with BMOC to expand operations of the Mall Café format of Baristas Coffee Company throughout the State of New York. The JV will be owned 51 percent by Baristas and 49 percent by BMOC.
The JV will be managed mainly by BMOC under the Baristas Café concept. The locations that are in malls in Pennsylvania are Baristas franchises owned and operated by BMOC Partners. Baristas Coffee Company will recognize revenue consistent with other majority owned JV’s in Florida.
Baristas Coffee Company, Inc. (BCCI), closed Wednesday's trading session at $0.0264, up 6.02%, on 1,040,185 volume with 48 trades. The average volume for the last 60 days is 1,049,656 and the stock's 52-week low/high is $0.02/$0.096.
5BARz International, Inc. (BARZ)
PennyStocks24 and Tip.us reported previously on 5BARz International, Inc. (BARZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed 5BARz International, Inc. is a technology leader in the cellular network extender industry. It focuses on the global commercialization of a patented product technology branded under the name 5BARz™. 5BARz™ is a cellular network infrastructure device for use in the small office, home, or for when users are mobile. 5BARz™ represents an important solution for cellular network operators in providing clear, high quality signal for their subscribers with a growing need for high quality connectivity. 5BARz International is headquartered in San Diego, California.
The Company’s products include the 5BARz Network Extender and the 5BARz Road Warrior. 5BARz™ incorporates a patented technology to create a highly engineered, single-piece, plug 'n play unit. It strengthens weak cellular signals to deliver high quality signals for voice, data, and video reception on cell phones and other cellular equipped devices.
5BARz International’s innovative product is the above-mentioned 5BARz Network Extender™. The 5Barz Network Extender™ is a “carrier grade” cellular network infrastructure device. It can be remotely managed from each carrier’s Network Operation Center.
It includes patented technologies, including bringing together the send and receive antenna into a single form factor, automatically cancels echo or “noise cancellation”, supports multiple bands and all frequencies around the world, and automatically balances power management to avoid any interference with the macro network. This is all while remaining very appealing to subscribers because of its small size (140mm X 100mm X 41mm) and minimal weight (300 grams). It can support up to ten simultaneous users at a time.
5BARz International is working with Grupo BTMex of Mexico City. Grupo BTMex’s specialization is in commercializing leading electronic brands in Mexico. 5BARz indicates that it is confident that together the two companies will be able to grow the Road Warrior business into Mexico in 2015.
5BARz has established a subsidiary Company, 5BARz India Private Ltd., in Bangalore, India. 5BARz India is a wholly-owned subsidiary of 5BARz. It will be licensed the exclusive rights to market and distribute all of 5BARz products throughout India in perpetuity. This subsidiary will be working with Flextronics, 5BARz International’s strategic manufacturing partner, in India as sales and production needs increase.
Recently, 5BARz International announced that its subsidiary, 5BARz India, unveiled the latest 5BARz® cellular network extender in India. 5BARz International CEO, Mr. Daniel Bland, stated that, “this product launch into the market in India, comprised of some 900 million subscribers, represents the culmination of seven years of research and development of our highly sophisticated cellular network extender. Users in India can expect a significant improvement in the performance of their cellular device comprised of clear voice communication, faster data transmission, improved battery life and reduced radiation from the cell phone when in use.”
5BARz International, Inc. (BARZ), closed Wednesday's trading session at $0.111, up 11.11%, on 517,430 volume with 59 trades. The average volume for the last 60 days is 177,455 and the stock's 52-week low/high is $0.039/$0.26.
Matinas BioPharma Holdings, Inc. (MTNB)
SmallCapVoice, Stock News Now, and Stock News reported on Matinas BioPharma Holdings, Inc. (MTNB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company with corporate headquarters in Bedminster, New Jersey. Established in 2011, Matinas’ emphasis is on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions. An experienced management team and a Board of Directors with a history of building pharmaceutical companies lead Matinas BioPharma Holdings. The Company’s shares trade on the OTCQB.
Matinas BioPharma’s focus is on creating highly differentiated, safe, and efficacious therapies using its expertise in drug formulation and development to address important unmet medical needs. Recent additions to the Company’s product pipeline, including MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies employing its proprietary lipid-crystal nano-particle cochleate formulations.
Matinas BioPharma earlier announced that upon a scheduled interim review, the study's Steering Committee recommended to stop enrollment early in its first-in-human study of investigational drug MAT9001 because of the study having enrolled a sufficient number of subjects (42 to date) required to demonstrate primary and secondary endpoints. The Company’s initial study is taking place in Canada and is a two-way crossover pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 versus an active prescription omega-3 medication comparator in subjects with high triglycerides (200-499 mg/dL).
MAT9001 is a proprietary prescription-only omega-3 fatty acid-based composition, consisting of docosa-pentaenoic acid (DPA) and other omega-3 fatty acids, which is under development for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) as the lead indication.
Matinas BipPharma filed an IND for MAT9001 in Q4 2014 with the Food and Drug Administration (FDA). It anticipates initiating a Phase 3 registration program pending two small studies and FDA agreement on the Phase 3 protocol. Matinas has purposely designed MAT9001 to provide a differentiated pharmacotherapy for the treatment of dyslipidemia.
Matinas also has its clinical development strategy for MAT2203, a novel lipid-crystal nano-particle orally delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and MAT2501, an early-stage program to treat gram-negative bacterial infections using an orally available formulation of Amikacin, a broad spectrum aminoglycoside.
In June, Matinas BioPharma announced the presentation of data from a head-to-head study that showed MAT9001, the prescription-only omega-3 fatty acid-based composition under development for the treatment of hypertriglyceridemia, demonstrated superiority versus Vascepa® (icosapent ethyl) in reducing lipids, triglycerides, and apolipoproteins and PCSK9 levels.
Matinas BioPharma Holdings, Inc. (MTNB), closed Wednesday's trading session at $1.00, even for the day, on 131,233 volume with 73 trades. The average volume for the last 60 days is 72,433 and the stock's 52-week low/high is $0.3101/$1.46.
Service Team, Inc. (SVTE)
Real Pennies reported previously on Service Team, Inc. (SVTE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Service Team, Inc., dba Delta Stag, is a manufacturer of commercial truck bodies and truck parts in the Southern California area. The Company acquired 100 percent of Delta Stag in June of 2013. Founded in 2011, Service Team has its headquarters in Villa Park, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.
Since June of 2013, Service Team has maintained a constant growth of greater than 30 percent per year. The Company manufactures truck bodies, which are attached to a truck chassis; as well as other products used by the trucking industry. The vans are available for hauling dry freight or refrigerated freight. Service Team provides its products to auto dealers and users of trucks, including dairies, food distributors, and local delivery.
The Company’s products include Refrigerated Body, Dry Freight Cargo Body, Furniture Body, Vendor Display Body, and Refrigerated Cargo Vans. Products also include Stake & Flat Beds as well as Refrigerated Cargo Trailers. Service Team has a large parts inventory and with its repair location can expedite returning an organization’s trucks to service.
Yesterday, Mr. Robert L. Cashman, President of Service Team, announced that the Company is continuing its practice of reporting positive results for the three month period ending May 31, 2015. Service Team reported sales of $709,520 and a net profit of $56,413. This is in comparison to the same period the year prior with sales of $450,237. This represents an increase of 58 percent over the prior period.
Overall performance for the nine months year to date totaled sales of $1,876,415 versus the nine month period of the prior year of $1,340,755. This represents an increase of 39 percent. Service Team has expensed all of the organization and acquisition cost of acquiring Trade Leasing, Inc. Moreover, Service Team is projecting annual sales of 2.6 million dollars with profits greater than $200,000 for the year ending August 31, 2015.
Service Team, Inc. (SVTE), closed Wednesday's trading session at $0.17, up 13.33%, on 42,239 volume with 24 trades. The average volume for the last 60 days is 3,469 and the stock's 52-week low/high is $0.10/$0.50.
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $14.00, off by 6.67%, on 1,900 volume with 9 trades. The stock’s average daily volume over the past 60 days is 843, and its 52-week low/high is $3.16/$16.50.
VistaGen Therapeutics Inc. reported today that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.S. National Institutes of Health (NIH) to initiate an NIH-funded Phase 2 clinical study of its orally active AV-101 in subjects with treatment-resistant Major Depressive Disorder (MDD). "The NIMH and several key leaders in the field with clinical experience using ketamine to treat MDD provided valuable expert advice on the design of our Phase 2 MDD study. We are grateful for their assistance. With their help, we have now achieved an important regulatory milestone for our AV-101 clinical development program," said H. Ralph Snodgrass, the Company's President and Chief Scientific Officer.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.1109, up 18.61%, on 9,952,627 volume with 980 trades. The stock’s average daily volume over the past 60 days is 4,027,284 and its 52-week low/high is $0.0035/$0.45.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Lauds Scope of Power Africa Initiative
Dominovas Energy Lands Historic Partnership With U.S. Government
Dominovas Energy Enters Second Power Provider Agreement in the Democratic Republic of the Congo
Well Power Inc. (WPWR)
The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0006, up 20.00%, on 10,259,485 volume with 28 trades. The stock’s average daily volume over the past 60 days is 17,032,934, and its 52-week low/high is $0.0003/$0.1395.
Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.
The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.
Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer
Well Power Inc. Company Blog
Well Power Inc. News:
Well Power Inc. Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors
Well Power - Letter from President to Shareholders
Well Power Inc. to host second webinar on proprietory micro-refinery technology
Growblox Sciences, Inc. (GBLX)
The QualityStocksDaily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.3699, up 5.69%, on 260,987 volume with 66 trades. The stock’s average daily volume over the past 60 days is 70,471, and its 52-week low/high is $0.151/$1.51.
Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.
Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.
Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer
Growblox Sciences, Inc. Company Blog
Growblox Sciences, Inc. News:
GrowBLOX Receives Funding to Complete Construction of Nevada Cultivation Facility
GrowBLOX Announces Deployment of Commercial Units
Growblox Sciences, Inc. (GBLX) is “One to Watch”
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.0465, up 7.89%, on 24,000 volume with 5 trades. The stock’s average daily volume over the past 60 days is 652,135, and its 52-week low/high is $0.041/$0.148.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Present at International Society for Cellular Therapy Annual Meeting
International Stem Cell Corporation Announces 2015 First Quarter Results
International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Today's Top 3
INO.com Market Report
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Aristocrat Group Corp. (ASCC) to Promote RWB Vodka at ‘World’s Premiere Cocktail Festival’
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Lauds Scope of Power Africa Initiative
- Galenfeha, Inc. (GLFH) Stored Energy Solutions Enters Aviation Industry
- Growblox Sciences, Inc. (GBLX) Receives Funding to Complete Construction of Nevada Cultivation Facility
- International Stem Cell Corp. (ISCO) to Present at International Society for Cellular Therapy Annual Meeting
- Loans4Less.com Inc. (LFLS) Enters into an Acquisition Agreement with 321LEND
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- On the Move Systems, Inc. (OMVS) Shared Economy Model Can Help Truckers Strengthen Local Networks
- One World Holdings, Inc. (OWOO) Announces Initial Order from Hallmark Stores
- Pure Hospitality Solutions, Inc. (PNOW) Releases Oveedia Site Snapshots
- View Systems, Inc. (VSYM) Files for Patent, Begins Manufacturing of Enhanced ViewScan Product
- VistaGen Therapeutics, Inc. (VSTA) Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors
- WRIT Media Group, Inc. (WRIT) Featured in Exclusive QualityStocks Production Video